Clinical Trial Terminology Explained

New from Johns Hopkins Health Alerts–The National Cancer Institute estimates that between 5% and 8% of cancer patients participate in clinical trials. Why is the number so low? Part of the problem is that many patients believe that all clinical trials include a placebo (an inactive treatment with no known therapeutic value)  and treat participants like “guinea pigs”–neither of which is true. To help clear up the confusion, this Johns Hopkins Health Alert explains clinical trial terminology, including randomization, placebo, and blinding. Click on the link to read the complete report: http://www.johnshopkinshealthalerts.com/alerts/prostate_disorders/JohnsHopkinsHealthAlertProstateDisorders_3263-1.html?ET=johnshopkins_blog:e34955:607412a:&st=email&st=email&s=EPH_091217_013

One Response to “Clinical Trial Terminology Explained”

  1. Terry Yake December 17, 2009 at 7:15 pm #

    RE: The reason drug/treatment trials have such low participation.

    Here are several more reasons that are just as important as the only reason you could come up with: distance between patient’s home and trial’s location, health state of patient, trial inclusion and exclusion criteria, timing of the patient’s diagnosis/availability and the trial study period, sponsor’s willingness to pay costs of the trial drug/treatment, wealth of the patient, unwillingness of the patient’s insurance to cover any of the costs, travel, and lodging.

    Beyond all these factors add in the type and aggressiveness of the disease of interest and you might also find the study period does not last long enough to sign up enough patients for a rare disease, or the study period doesn’t last long enough to determine survival statistics.

Leave a Reply:

Gravatar Image